Respiratory Syncytial Virus Clinical Trial
Official title:
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)
This was a randomized, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered EDP-938 in adults with RSV infection.
Subjects (aged 18 to 75 years, inclusive) with up to 48 hours of upper respiratory tract infection (URTI) symptoms who tested positive for respiratory syncytial virus (RSV) and negative for influenza virus by rapid testing (ie, Rapid Viral Screen). Subjects with stable asthma or chronic obstructive pulmonary disease (COPD) were allowed in the study. Eighty-two (82) subjects were enrolled in this Phase 2b, randomized, double-blind, placebo-controlled, multicentre study of EDP-938 administered orally for the treatment of acute URTI with confirmed RSV infection in ambulatory adult subjects. For each subject, the duration of study participation was approximately 2 weeks and consisted of 3 periods: Screening (occurs on Day1), Treatment (5 days), and Follow-up (9 days after last dose). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04528719 -
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive
|
Phase 1 | |
| Terminated |
NCT02508194 -
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
|
Phase 2 | |
| Active, not recruiting |
NCT06060457 -
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
|
Phase 3 | |
| Terminated |
NCT01757496 -
Cough Assist in Bronchiolitis
|
N/A | |
| Completed |
NCT00100373 -
RSV Challenge in Healthy Adults
|
N/A | |
| Completed |
NCT03524118 -
Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05572658 -
Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
|
||
| Recruiting |
NCT06067230 -
A Study to Investigate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults
|
Phase 3 | |
| Completed |
NCT00246480 -
RSV Disease in the Elderly
|
||
| Active, not recruiting |
NCT06097299 -
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
|
Phase 2 | |
| Completed |
NCT00889070 -
Respiratory Events Among Premature Infants
|
N/A | |
| Unknown status |
NCT00613184 -
Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses
|
N/A | |
| Completed |
NCT05559905 -
Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)
|
Phase 2 | |
| Active, not recruiting |
NCT05127434 -
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
|
Phase 2/Phase 3 | |
| Terminated |
NCT04978337 -
A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
|
Phase 2 | |
| Recruiting |
NCT06143046 -
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
|
Phase 2 | |
| Active, not recruiting |
NCT05397223 -
A Study of Modified mRNA Vaccines in Healthy Adults
|
Phase 1 | |
| Completed |
NCT02472548 -
A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine
|
Phase 1 | |
| Completed |
NCT01562938 -
MEDI-557 Adult Dosing
|
Phase 1 | |
| Completed |
NCT01734668 -
Sofia RSV FIA Field Study
|
N/A |